Abstract
Inherited retinal diseases, such as retinitis pigmentosa (RP), can be caused by thousands of different mutations, a small number of which have been successfully treated with gene replacement. However, this approach has yet to scale and may not be feasible in many cases, highlighting the need for interventions that could benefit more patients. Here, we found that microglial phagocytosis is upregulated during cone degeneration in RP, suggesting that expression of “don’t-eat-me” signals such as CD47 might confer protection to cones. To test this, we delivered an adeno-associated viral (AAV) vector expressing CD47 on cones, which promoted cone survival in 3 mouse models of RP and preserved visual function. Cone rescue with CD47 required a known interacting protein, signal regulatory protein α (SIRPα), but not an alternative interacting protein, thrombospondin-1 (TSP1). Despite the correlation between increased microglial phagocytosis and cone death, microglia were dispensable for the prosurvival activity of CD47, suggesting that CD47 interacts with SIRPα on nonmicroglial cells to alleviate degeneration. These findings establish augmentation of CD47/SIRPα signaling as a potential treatment strategy for RP and possibly other forms of neurodegeneration.
Highlights
A major obstacle in developing treatments for inherited retinal diseases (IRDs) is the enormous genetic heterogeneity of pathogenic mutations
To assess if microglia during the later stages of retinitis pigmentosa (RP) might phagocytose cones, retinas from these mice were immunostained for cone arrestin, a marker of all cones
To more sensitively measure microglial phagocytic activity, we explanted retinas from rd1;CX3CR1GFP/+ and sighted CX3CR1GFP/+ animals and incubated them with yeast particles conjugated to pHrodo Red, a pH-dependent dye that fluoresces upon lysosomal acidification
Summary
A major obstacle in developing treatments for inherited retinal diseases (IRDs) is the enormous genetic heterogeneity of pathogenic mutations. For a minority of IRDs, gene replacement therapy with adeno-associated viral (AAV) vectors has led to promising results in clinical trials and, in one instance, a successful commercial drug [1, 2]. This strategy has yet to reach the vast majority of patients and may not be feasible for those with less common, gain-of-function, or unidentified mutations. Given these challenges, another approach to treating RP and other IRDs would be to develop mutation-agnostic therapies that preserve cone photoreceptors. Regardless of the exact etiology, an intervention capable of protecting cones in RP independent of the initial genetic lesion would potentially be beneficial for many patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.